Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL CAPECITABINE INDUSTRY
2.1 Summary about Capecitabine Industry
2.2 Capecitabine Market Trends
2.2.1 Capecitabine Production & Consumption Trends
2.2.2 Capecitabine Demand Structure Trends
2.3 Capecitabine Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 500 mg
4.2.2 150 mg
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Breast Cancer
4.3.2 Colorectal cancer
4.3.3 Stomach Cancer
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 500 mg
5.2.2 150 mg
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Breast Cancer
5.3.2 Colorectal cancer
5.3.3 Stomach Cancer
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 500 mg
6.2.2 150 mg
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Breast Cancer
6.3.2 Colorectal cancer
6.3.3 Stomach Cancer
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 500 mg
7.2.2 150 mg
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Breast Cancer
7.3.2 Colorectal cancer
7.3.3 Stomach Cancer
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 500 mg
8.2.2 150 mg
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Breast Cancer
8.3.2 Colorectal cancer
8.3.3 Stomach Cancer
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 500 mg
9.2.2 150 mg
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Breast Cancer
9.3.2 Colorectal cancer
9.3.3 Stomach Cancer
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Teva
10.1.2 Roche
10.1.3 Mylan
10.1.4 Hikma
10.1.5 Hengrui Medicine
10.1.6 Cipla
10.1.7 Reliance Group
10.1.8 Hetero
10.2 Capecitabine Sales Date of Major Players (2017-2020e)
10.2.1 Teva
10.2.2 Roche
10.2.3 Mylan
10.2.4 Hikma
10.2.5 Hengrui Medicine
10.2.6 Cipla
10.2.7 Reliance Group
10.2.8 Hetero
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
